Compound Detail
CHEMBL3137308
PEFICITINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Basic Information
| ChEMBL ID | CHEMBL3137308 |
| Name | PEFICITINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | DREIJXJRTLTGJC-ZLBJMMTISA-N |
| Therapeutic | ✓ Yes |
4
Targets
20
Activities
1
Assay Types
0
PK Parameters
20
Publications
4
Known Names
5
Indications
1
Mechanisms
Molecular Properties
326.4
MW (Da)
2.01
ALogP
4
HBA
4
HBD
104.0
PSA (Ų)
0.69
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2019 |
| Availability | Unknown |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Janus Kinase (JAK) inhibitor | INHIBITOR | Janus Kinase (JAK) | ✓ | ✓ |
Indications
Arthritis, Rheumatoid Colitis, Ulcerative Psoriasis Kidney Diseases Liver Diseases
ATC Classification
L04AF06
peficitinib
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS
Activity Summary
IC50 20 meas. best 9.15
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Tyrosine-protein kinase JAK3 CHEMBL2148 | IC50 | 9.15 | 8.86 | 0.7 | 5 |
| Tyrosine-protein kinase JAK1 CHEMBL2835 | IC50 | 8.41 | 8.19 | 3.9 | 5 |
| Non-receptor tyrosine-protein kinase TYK2 CHEMBL3553 | IC50 | 8.32 | 8.028 | 4.8 | 5 |
| Tyrosine-protein kinase JAK2 CHEMBL2971 | IC50 | 8.3 | 8.09 | 5.0 | 5 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine